Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma.
Posterior leukoencephalopathy syndrome is a recently described syndrome involving mainly parieto-occipital gray/white matter of the brain. It occurs secondary to various clinical entities, like hypertension and immunosuppressive therapy. Few cases after combination chemotherapy have been reported. This study describes a 36-year-old woman with primary refractory T-cell lymphoma, who developed central nervous system toxicity due to treatment with intrathecal methotrexate and intravenous ifosfamide, idarubicine and etoposide given as a salvage regimen. Both clinical features as well as magnetic resonance imaging findings were typical for posterior leukoencephalopathy syndrome. The patient died despite anti-hypertensive therapy and haemodialysis. Central nervous system toxicity related to chemotherapeutics and posterior leukoencephalopathy syndrome are discussed briefly.
Abali
H
H
Department of Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey.
Eren
O O
OO
Dizdar
O
O
Karadağ
O
O
Erman
M
M
Yilmaz
A
A
Uluç
K
K
Erdem
I
I
Türker
A
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001706:Biopsy; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007069:Ifosfamide / Q000008:administration & dosage; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000473:pathology; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging
D006454:Hemoglobins; D005047:Etoposide; D007069:Ifosfamide; D015255:Idarubicin